Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer

Maura N. Dickler, Melody A. Cobleigh, Kathy Miller, Pamela M. Klein, Eric P. Winer

Research output: Contribution to journalArticle

85 Citations (Scopus)

Abstract

Purpose To evaluate the efficacy and safety of erlotinib in advanced breast cancer. Experimental design Multicenter, phase II study of erlotinib (150 mg orally daily). Cohort 1: progression after anthracyclines, taxanes, and capecitabine (n = 47). Cohort 2: progression after >1 chemotherapy for advanced-stage disease (n = 22). Primary endpoint was response rate (World Health Organization criteria). Secondary endpoints were safety, time to progression, and survival. Results One patient in each cohort (n = 2, 3.0%) had a partial response. Response duration was 17 weeks for the Cohort 1 patient and 32 weeks for the Cohort 2 patient. Median time to progression was 43 days for Cohort 1 (range 1-204) and 43 days for Cohort 2 (range 25-419). Common adverse events were diarrhea, rash, dry skin, asthenia, nausea, anorexia. Conclusion Erlotinib had minimal activity in unselected previously treated women with advanced breast cancer. Predictive factors are needed to identify breast cancer patients who may derive benefit from erlotinib treatment.

Original languageEnglish
Pages (from-to)115-121
Number of pages7
JournalBreast Cancer Research and Treatment
Volume115
Issue number1
DOIs
StatePublished - May 2009

Fingerprint

Breast Neoplasms
Safety
Asthenia
Taxoids
Anthracyclines
Anorexia
Exanthema
Nausea
Diarrhea
Research Design
Drug Therapy
Survival
Erlotinib Hydrochloride
Therapeutics
Capecitabine

Keywords

  • Epidermal growth factor receptor (EGFR/HER1)
  • Erlotinib
  • Metastatic breast cancer
  • Patient selection

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer. / Dickler, Maura N.; Cobleigh, Melody A.; Miller, Kathy; Klein, Pamela M.; Winer, Eric P.

In: Breast Cancer Research and Treatment, Vol. 115, No. 1, 05.2009, p. 115-121.

Research output: Contribution to journalArticle

Dickler, Maura N. ; Cobleigh, Melody A. ; Miller, Kathy ; Klein, Pamela M. ; Winer, Eric P. / Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer. In: Breast Cancer Research and Treatment. 2009 ; Vol. 115, No. 1. pp. 115-121.
@article{d65210e01196432798488aa1fd63b89b,
title = "Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer",
abstract = "Purpose To evaluate the efficacy and safety of erlotinib in advanced breast cancer. Experimental design Multicenter, phase II study of erlotinib (150 mg orally daily). Cohort 1: progression after anthracyclines, taxanes, and capecitabine (n = 47). Cohort 2: progression after >1 chemotherapy for advanced-stage disease (n = 22). Primary endpoint was response rate (World Health Organization criteria). Secondary endpoints were safety, time to progression, and survival. Results One patient in each cohort (n = 2, 3.0{\%}) had a partial response. Response duration was 17 weeks for the Cohort 1 patient and 32 weeks for the Cohort 2 patient. Median time to progression was 43 days for Cohort 1 (range 1-204) and 43 days for Cohort 2 (range 25-419). Common adverse events were diarrhea, rash, dry skin, asthenia, nausea, anorexia. Conclusion Erlotinib had minimal activity in unselected previously treated women with advanced breast cancer. Predictive factors are needed to identify breast cancer patients who may derive benefit from erlotinib treatment.",
keywords = "Epidermal growth factor receptor (EGFR/HER1), Erlotinib, Metastatic breast cancer, Patient selection",
author = "Dickler, {Maura N.} and Cobleigh, {Melody A.} and Kathy Miller and Klein, {Pamela M.} and Winer, {Eric P.}",
year = "2009",
month = "5",
doi = "10.1007/s10549-008-0055-9",
language = "English",
volume = "115",
pages = "115--121",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "1",

}

TY - JOUR

T1 - Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer

AU - Dickler, Maura N.

AU - Cobleigh, Melody A.

AU - Miller, Kathy

AU - Klein, Pamela M.

AU - Winer, Eric P.

PY - 2009/5

Y1 - 2009/5

N2 - Purpose To evaluate the efficacy and safety of erlotinib in advanced breast cancer. Experimental design Multicenter, phase II study of erlotinib (150 mg orally daily). Cohort 1: progression after anthracyclines, taxanes, and capecitabine (n = 47). Cohort 2: progression after >1 chemotherapy for advanced-stage disease (n = 22). Primary endpoint was response rate (World Health Organization criteria). Secondary endpoints were safety, time to progression, and survival. Results One patient in each cohort (n = 2, 3.0%) had a partial response. Response duration was 17 weeks for the Cohort 1 patient and 32 weeks for the Cohort 2 patient. Median time to progression was 43 days for Cohort 1 (range 1-204) and 43 days for Cohort 2 (range 25-419). Common adverse events were diarrhea, rash, dry skin, asthenia, nausea, anorexia. Conclusion Erlotinib had minimal activity in unselected previously treated women with advanced breast cancer. Predictive factors are needed to identify breast cancer patients who may derive benefit from erlotinib treatment.

AB - Purpose To evaluate the efficacy and safety of erlotinib in advanced breast cancer. Experimental design Multicenter, phase II study of erlotinib (150 mg orally daily). Cohort 1: progression after anthracyclines, taxanes, and capecitabine (n = 47). Cohort 2: progression after >1 chemotherapy for advanced-stage disease (n = 22). Primary endpoint was response rate (World Health Organization criteria). Secondary endpoints were safety, time to progression, and survival. Results One patient in each cohort (n = 2, 3.0%) had a partial response. Response duration was 17 weeks for the Cohort 1 patient and 32 weeks for the Cohort 2 patient. Median time to progression was 43 days for Cohort 1 (range 1-204) and 43 days for Cohort 2 (range 25-419). Common adverse events were diarrhea, rash, dry skin, asthenia, nausea, anorexia. Conclusion Erlotinib had minimal activity in unselected previously treated women with advanced breast cancer. Predictive factors are needed to identify breast cancer patients who may derive benefit from erlotinib treatment.

KW - Epidermal growth factor receptor (EGFR/HER1)

KW - Erlotinib

KW - Metastatic breast cancer

KW - Patient selection

UR - http://www.scopus.com/inward/record.url?scp=67349087409&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67349087409&partnerID=8YFLogxK

U2 - 10.1007/s10549-008-0055-9

DO - 10.1007/s10549-008-0055-9

M3 - Article

VL - 115

SP - 115

EP - 121

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 1

ER -